ÂÜÀòÂÒÂ×

Carlos Castro Gonzalez is the CEO of Leuko. Prior to joining Leuko, they were a M+Vision Fellow at the Massachusetts Institute of Technology (MIT) from July 2013 to June 2018. In this role, they identified unmet clinical needs and led the conception, development and management for novel lines of research. Carlos also assembled collaborative teams composed by engineers, physicians and entrepreneurs to develop technical solutions in the healthcare space. Furthermore, they coordinated and managed R&D teams (6-10 people), applied image processing algorithms to microscopy and ultrasound data with applications in cancer care and meningitis diagnosis, designed and executed five clinical human studies, and successfully competed for external follow-on funding ($1.5M). Additionally, Carlos managed and communicated projects through a working group, with attention to milestones, delegation of team work and documentation. Carlos also assessed technology readiness level, market estimation, cost analysis, IP analysis and regulatory requirements for a healthcare venture. Carlos has also reviewed for BMC Bioinformatics, IEEE Transactions on Medical Imaging and GigaScience. Carlos has mentored undergraduate and graduate students and communicated results to technical and nontechnical audiences. Prior to their role at MIT, Carlos was a Visiting Scientist at École Polytechnique from December 2010 to March 2011.

Carlos Castro Gonzalez has a PhD in Biomedical/Medical Engineering from Universidad Politécnica de Madrid, an MSc in Wireless Systems and Signal Processing from KTH Royal Institute of Technology, and a BEng in Telecommunications Engineering from Universidad Politécnica de Madrid.

Some individuals on their team include Alberto Pablo Trinidad - Machine Learning Engineer, Aurelien Bourquard - Chief Data Scientist, and Alvaro Sanchez - Ferro - Chief Medical Officer.